The phase three human clinical trial of Covaxin, a vaccine against the novel coronavirus, began at the AIIMS in New Delhi on Thursday.
(Representative image)
The phase three human clinical trial of Covaxin, a vaccine against the novel coronavirus, began at the AIIMS in New Delhi on Thursday. The trial began when Dr. MV Padma Srivastava, head of the Neuroscience Center at the main institute, and three other volunteers received the first dose.
The potential anti-coronavirus developed, Covaxin, is being created by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
Dr Srivastava was the first to receive the first test dose, which would be administered to nearly 15,000 volunteers at Delhi’s AIIMS Hospital in the coming days, the sources said.
“Covaxin is the first indigenously developed coronavirus vaccine, and in addition to that, my institute is participating in the trial. I am honored to be the first volunteer to receive the vaccine. I am happy to be part of a great” I am perfectly fine fine and I’m working, “PTI news agency quoted Srivastava on.
Based on the trial process, a 0.5 ml dose would be administered on day 0 and day 28, sources told PTI.
In addition to Covaxin in India, four other potential vaccines are in various phases of human clinical trials with the Serum Institute of India conducting the phase three trial of the Oxford-Astrazeneca Covid-19 vaccine, while the indigenously developed vaccine by Zydus Cadila has completed phase two. clinical trial in the country, PTI had previously reported.
Read also | A US study finds that smartwatches can detect the first signs of Covid-19 in the body 9 days before symptoms appear
Read also | From Pfizer to Covaxin: An Overview of the Covid-19 Vaccine Candidates for India
